WO2022228134A1 - Oil-in-water emulsions and uses thereof in resisting infantile eczema - Google Patents

Oil-in-water emulsions and uses thereof in resisting infantile eczema Download PDF

Info

Publication number
WO2022228134A1
WO2022228134A1 PCT/CN2022/086724 CN2022086724W WO2022228134A1 WO 2022228134 A1 WO2022228134 A1 WO 2022228134A1 CN 2022086724 W CN2022086724 W CN 2022086724W WO 2022228134 A1 WO2022228134 A1 WO 2022228134A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
parts
water
emulsion
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/086724
Other languages
English (en)
French (fr)
Inventor
Zhengmei HUANG
Jinping DING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Benzhen Cosmetics Co Ltd
Original Assignee
Shandong Benzhen Cosmetics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Benzhen Cosmetics Co Ltd filed Critical Shandong Benzhen Cosmetics Co Ltd
Priority to US18/556,825 priority Critical patent/US20250281443A1/en
Priority to JP2023565903A priority patent/JP2024515787A/ja
Priority to EP22794605.0A priority patent/EP4329719A4/en
Publication of WO2022228134A1 publication Critical patent/WO2022228134A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A61K35/06—Mineral oils, e.g. paraffinic oils or aromatic oils based on aromatic hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/48—Thickener, Thickening system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present disclosure relates to oil-in-water emulsions, particularly to emulsions for infantile eczema, which do not contain traditional preservatives and emulsifiers.
  • Infants’ skins are not as strong as mature skins, and more likely to increase epidermal water loss and stratum corneum hydration to result in reduced effectiveness of a skin barrier function. Because of a higher proportion between body surface and body weight of infants, topical medications are more easily absorbed and can have a more noticeable effect on the infants’ skins. The skins of infants are more vulnerable to the environment than those of adults, become dry, and are prone to atopic dermatitis, diaper dermatitis and even infection.
  • Petrolatum such as vaseline are known to be an effective raw material to improve infantile eczema.
  • the petrolatum is an oily substance with strong polarity, and can block pores to hinder the normal physiological function of the skin in addition to poor use experience if being directly used onto the skins of infants with eczema.
  • the petrolatum is used in a form of emulsion, it is generally needed to add emulsifiers and other ingredients, which can pose a potential health risk.
  • CN106075120A discloses an eczema cream comprising: 25-35 parts of ⁇ -glucan, 2-10 parts of purslane extract, 0.1-2 parts of notoginseng triterpenes, 5-20 parts of natural vegetable oil, 2-6 parts of emulsifier and 20-80 parts of purified water.
  • the eczema cream realizes the effect of removing eczema through ⁇ -glucan, purslane extract, panax notoginsenosides and natural vegetable oil.
  • many emulsifiers are used in this product, which poses a potential threat to infant skins.
  • CN1466952A discloses that laminarin is a hydrocarbon which belongs to ⁇ -glucan.
  • the laminarin exists in mushrooms such as shiitake mushrooms, seaweeds such as kelp, and has the effect of improving immunity. It is known that it is difficult to be separately absorbed, and suitably ingested together with proteins. However, this product does not disclose how to be applied to treatment of infantile eczema.
  • CN106176507A discloses an eczema-removal emulsion containing: 0.1-3 parts of Centella asiatica extract, 0.1-1 part of marrubium vulgare extract, 0.1-5 parts of yeast ⁇ -glucan and 0.1-3 parts of dragon head bamboo extract.
  • This product uses medicinal plant extracts and other ingredients as active ingredients to alleviate eczema. For infant products, their safety are not guaranteed.
  • CN109431943A discloses a repairing cream for infantile eczema, comprising: holy basil extract, avena strigosa seed extract, inverted bell extract, ribes nigrum extract, blue thistle oil, moringa oleifera seed oil, Echinacea purpurea extract, egg yolk oil, emollient, moisturizer, antioxidant, antiallergic agent, thickener, emulsifier, co-emulsifier, preservative, etc.
  • This product contains the preservative, flavors, the emulsifier and the like which possess potential safety risks for infant skins.
  • CN108771649A discloses a baby redoubling-moisturizing cream containing shea butter, comprising: shea butter fruit fat, betaine, trehalose, flavor, rhodiola, centella asiatica extract, polygonum cuspidatum root extract, scutellaria root extract, wild chrysanthemum extract, etc.
  • the moisturizing cream containing shea butter and other ingredients can redouble to moisturize the skins of the children to realize deep nourishing and moisturizing.
  • this product contains preservatives, flavors, emulsifiers and the like which possess other potential safety risks for infant skins.
  • CN108778240A discloses an infant skin care product, which comprises medical grade water, at least one stabilizer, at least one nutrient and at least one emulsifier.
  • the infant skin care product can also comprise zinc gluconate, magnesium aspartate, copper gluconate (composite trace element) and dunaliella salina extract, among them, stable ingredients include shea butter and other ingredients, but the product contains emulsifiers, which have potential safety risks to infant skin.
  • CN109431838A discloses that an essence product that does not contain emulsifiers is prepared by compounding behenyl alcohol, cetearyl alcohol and dipalmitoyl hydroxyproline to replace the traditional emulsifiers.
  • this product is mainly an aqueous solution, in which only a small amount of oil phase components and substances with preservative functions such as 1, 2-pentanediol are used, and these ingredients have no good inhibition effect on eczema.
  • CN111264863A discloses that an emulsion is prepared by using a composite formed by proanthocyanidins and oat ⁇ -glucan as an emulsifier, the prepared emulsion has attractive reddish-brown appearance and stability, and meanwhile has the function of protecting functional oil or fat soluble biological active ingredients.
  • this product is not publicly used for removing infantile eczema.
  • CN111346053A discloses that an emulsifier is prepared by using ⁇ -glucan, which is a stable emulsion containing olive oil.
  • ⁇ -glucan is cultured and obtained by using a special preparation method, but it cannot be determined whether the emulsifier is suitably used as an oil ingredient for infantile eczema and whether additional stable ingredients such as preservatives are required.
  • US2011168055A1 discloses an emulsion that contains (1 ⁇ 3) - ⁇ -D-glucan based on the total weight of 0.01 to 10 weight parts of the emulsion.
  • the emulsion contains a bituminous binder which is not disclosed to be used for resisting infantile eczema.
  • US2012045422A1 discloses a method for treating or preventing eczema in a subject, which includes administering lactobacillus rhamnosus to a subject in need.
  • WO2020191620A1 has disclosed that an exemplary natural skin care emulsion without preservatives contains 5-30 parts of glycerol, 5-30 parts of betaine, 5-20 parts of xylitol, 5-30 parts of fructose, 30-40 parts of plant extracts and 0.1-0.5 parts of xanthan gum.
  • the oil phase contains 1-2 parts of soybean lecithin, 5-15 parts of shea butter, 5-15 parts of olive oil and 1-10 parts of sea buckthorn oil. This product still contains an emulsifier ingredient, and it cannot be determined whether it is effective for infantile eczema.
  • Emulsifiers used in lotions and creams of infant products can emulsify the sebum in the infant stratum corneum, causing the water to wash away the stratum corneum sebum and destroying the protective barrier function of the skin. Exogenous substances can cause skin irritation and lead to anaphylaxis. All types of perfumes and dyes used currently have the risk of sensitization and allergic reactions.
  • One objective of the present disclosure is to provide a low irritation, more safe and stable and long term storable skin care product, which has a good improvement effect on infantile eczema.
  • the inventors unexpectedly found that the stability of an emulsion with high content of the petrolatum or shea butter can be stabilized by Sclerotium Gum, so as to prepare the petrolatum or shea butter into the emulsion, thereby avoiding the use of emulsifier components and improving use experience and eczema-resisting effects.
  • the inventors unexpectedly found that the emulsions prepared from Sclerotium Gum and water as well as water-soluble components selected from betaine, glycerol, sorbitol and/or a combination thereof, having a water activity 0f 0.75 or less, are effective in controlling the existence of microorganisms, thereby avoiding the use of preservative ingredients.
  • the present disclosure provides an oil-in-water emulsion, based on the total weight of the emulsion, comprising:
  • the emulsion having a water activity of 0.75 or less.
  • an oil-in-water emulsion based on the total weight of the emulsion, comprising:
  • the emulsion having a water activity of 0.75 or less.
  • the present disclosure relates to an oil-in-water emulsion, based on the total weight of the emulsion, comprising
  • the emulsion having a water activity of 0.75 or less.
  • an oil-in-water emulsion based on the total weight of the emulsion, comprising:
  • the emulsion having a water activity of 0.75 or less.
  • an oil-in-water emulsion based on the total weight of the emulsion, comprising:
  • the emulsion having a water activity of 0.75 or less.
  • any one of the above oil-in-water emulsions they do not contain a preservative.
  • any one of the above oil-in-water emulsions do not contain a surfactant.
  • kits comprising:
  • a first moisturizing cream selected from any one of the oil-in-water emulsion of the present disclosure
  • a second aqueous solution containing 95-100 parts by weight of water and 0-5 parts by weight of optional water-soluble active ingredients.
  • the present disclosure also relates to a method for caring for skins, comprising the following steps:
  • step (3) evenly smearing the mixture obtained in step (2) on skins;
  • the steps (1) and (2) can be implemented on skins in turn or simultaneously.
  • the present disclosure relates to an application of the oil-in-water emulsion in preparation of cosmetics and/or medicines for infantile eczema.
  • Sclerotium rolfsii is a fungus existing in soil. It produces Sclerotium Gum via fermentation.
  • the Sclerotium Gum is a common cosmetic ingredient and can be widely applied.
  • the Sclerotium Gum is most commonly used as a thickener or a gelling agent, has high thermal stability, can help to enhance the moisture barrier of the skin, prevents moisture loss through epidermis and helps to keep the skin moist.
  • the Sclerotium Gum used in the present disclosure has the following chemical structure:
  • the amount of the Sclerotium Gum is based on parts by weight, the oil-in-water emulsion contains 0.1-2 parts by weight, preferably 0.1-1 weight, especially preferably 0.18 part by weight, of Sclerotium Gum.
  • the Sclerotium Gum suitable in the present application has a viscosity of greater than 1000 mPa ⁇ s when its active matter content is 0.5%, preferably greater than 2000 mPa ⁇ s, especially preferably greater than 4000 mPa ⁇ s, especially the Sclerotium Gum produced by Onlystar.
  • the petrolatum (also referred to as vaseline) has a compositions being between C 17 H 36 and C 21 H 44 and is a high molecular hydrocarbon obtained from petroleum fractions with a distillation end temperature above 303°C.
  • the petrolatum has a specific gravity of between 0.820 and 0.865 and is insoluble in water, but is easily soluble in gasoline and pine oil.
  • the vaseline prepared by deep refining is a colorless, odorless, non-fluorescent and transparent oily liquid with a melting point of about 37-54°C, does not contain any additives, moisture and mechanical impurities, and is insoluble in water.
  • the vaseline is an alkane, and therefore has extremely stable chemical property, good anti-oxidation safety, stability and light safety.
  • the vaseline cannot be utilized by microorganisms, is difficult to decay and deteriorate, and is not easily generate character change.
  • the petrolatum of the present disclosure preferably uses pharmaceutical grade vaseline.
  • the oil-in-water emulsion contains 5.0-25.0 parts by weight, preferably 10-25 parts by weight, especially preferably 15-20 parts by weight, of petrolatum.
  • the present disclosure further optionally contains water-soluble active ingredients without special limitations.
  • the water-soluble active ingredients of the present disclosure comprise water-soluble active ingredients beneficial to improving skin conditions, for example prebiotics derived from a lactic acid extract, and its amount is 0-5 parts by weight.
  • the water-soluble active ingredient can exist in the first moisturizing cream or the second aqueous solution alone or simultaneously.
  • the oil-in-water emulsion of the present disclosure does preferably not contain surfactants.
  • surfactant of the present disclosure is also referred to as an interfacial surfactant, which is generally a substance having an emulsifying effect in the present disclosure, and is a substance capable of reducing the surface tension of the liquid or the interfacial tension between two phases.
  • the surfactant is amphiphilic and contains hydrophilic and lipophilic groups.
  • hydrophilic groups include but are not limited to amino groups, carboxyl groups, sulfonic groups, hydroxyl groups, etc.
  • hydrophobic groups include but are not limited to aliphatic alkanes, olefins, alkynes and aromatic hydrocarbons of C8 and above.
  • commonly used surfactants include, but are not limited to, natural surfactants or derivatives thereof and synthetic surfactants.
  • natural surfactants or derivatives thereof are protein based surfactants.
  • anionic surfactants for example, water-soluble salts of higher fatty acid monoglyceride monosulfate, such as sodium salts of monosulfated monoglyceride of hydrogenated coconut oil fatty acid, such as sodium N-methyl N-coconut acyl taurine and sodium coconut oil glyceride sulfate; higher alkyl sulfate, such as sodium lauryl sulfate; higher alkyl ether sulfates, such as sodium lauryl alcohol polyether-2 sulfate; higher alkyl aryl sulfonates, such as sodium dodecylbenzene sulfonate (sodium lauryl benzene sulfonate) ; Higher alkyl sulfoacetates, such as sodium lauryl sulfoacetate (sodium dodecyl sulfoacetate) , higher fatty acid esters of 1, 2-dihydroxypropane sulfonic acid
  • the cationic surfactants described in the present disclosure can be broadly defined as derivatives of aliphatic quaternary ammonium compounds with a long alkyl chain containing 8-18 carbon atoms, such as lauryl trimethylammonium chloride, cetyl pyridine chloride, cetyl trimethylammonium bromide, diisobutyl phenoxyethyl dimethyl benzyl ammonium chloride, coconut alkyl trimethylammonium nitrite, cetyl pyridine fluoride and their mixtures.
  • non-ionic surfactants can be broadly defined as compounds produced by condensation of alkene oxide groups with organic hydrophobic compounds that can be essentially aliphatic or alkyl aromatic compounds.
  • suitable nonionic surfactants include, but are not limited to, polyethylene oxide condensates of alkyl phenols, condensation products derived from the reaction products of ethylene oxide with propylene oxide and ethylenediamine, ethylene oxide condensates of aliphatic alcohols, long-chain tertiary amine oxides, long-chain tertiary phosphine oxides, long-chain dialkyl sulfoxides, and mixtures of such substances, such as poloxamer, polysorbate and polyethylene glycol hydrogenated castor oil.
  • amphoteric surfactants include: betaine (such as coconut amide propyl betaine) ; derivatives of aliphatic secondary and tertiary amines, wherein the aliphatic group can be straight or branched chain, and one of the aliphatic substituents contains about 8-18 carbon atoms and one of the aliphatic substituents contains anionic water solubilizing groups (such as carboxylate, sulfonate, sulfate, phosphate or phosphonate) ; and mixtures of such the materials.
  • betaine such as coconut amide propyl betaine
  • anionic water solubilizing groups such as carboxylate, sulfonate, sulfate, phosphate or phosphonate
  • the emulsion of the present disclosure does not contain preservatives and bacteriostatic agents.
  • the preservatives and bacteriostatic agents are selected from alcohols, formaldehyde donors and aldehyde derivatives, benzoic acid and its derivatives and other organic compounds. For example, phenoxyethanol, benzyl alcohol, imidazolidinyl urea, p-hydroxybenzoic acid esters, bronopol, carson and quaternary ammonium salts, etc.
  • the water activity of the emulsion is adjusted to no more than 0.75 through water, betaine and optional water-soluble polyols and/or water-soluble polysaccharides to inhibit the growth of microorganisms. Therefore, the water activity of the oil-in-water emulsion of the present disclosure is less than or equal to 0.75, preferably less than or equal to 0.65, especially preferably less than or equal to 0.6.
  • the oil-in-water emulsion according to the present disclosure can thicken the skin barrier layer of the infant, improve the moisture retention ability of the skin, and prevent the external risk ingredients from entering the skin to cause allergy.
  • the emulsion material of the present disclosure is inert and safe, and can prevent formula ingredients from permeating into the skin to cause allergy.
  • the present disclosure does not use emulsifiers, so as to reduce the damage to the skin barrier caused by emulsifiers.
  • the present disclosure does not use bacteriostatic agents or preservatives to protect the microbiota on the infant skin.
  • Fig. 1 is an infrared spectrum of Sclerotium Gum used in the present disclosure.
  • Fig. 2 shows emulsion stability of different Sclerotium Gum systems.
  • Fig. 3 shows emulsion stability of different Sclerotium Gum systems.
  • Fig. 4 is a microscope image of example 1 (1-3 and blank control) .
  • Fig. 5 shows use of a moisturizing cream in example 6 for back eczema of three-month-old infants.
  • Fig. 6 shows use of a moisturizing cream in example 6 for facial eczema of 42-day-old infants.
  • Fig. 7 shows use of a moisturizing cream in example 6 for facial eczema of 4-month-old infants.
  • Example 1 oil-in-water emulsions and the stability test
  • the oil-in-water emulsions are prepared respectively through a formula in Table 1 (in parts by weight) .
  • the prepared samples were put at room temperature for 24 h to observe the stability, that is, to observe whether oil droplets were separated out. If no oil droplets were separated out, it is determined that the stability is passed (+) , or else the stability is not passed (-) .
  • the results are as shown in Figs. 2-3.
  • Centrifugation experiment the prepared samples were pre-heated in a 38°Cconstant-temperature incubator for 1 h, and then transferred to a centrifuge to be centrifuged for 30 min at 2000 r/min, and the samples centrifuged were taken out for observation. If there is no delamination, it is determined that the stability is passed, or else the stability is not passed.
  • the prepared samples were put in a 50°C constant-temperature incubator, and taken out after 6 weeks to observe whether there is oil-water delamination. If there is no oil-water delamination, it is determined that the stability is passed (+) , or else the stability is not passed (-) .
  • Microscope examinations for formula 1-3 and blank control show that the oil-in-water emulsion with Sclerotium Gum can form homogeneous oil droplets, while the oil droplet of the oil-in-water emulsion without Sclerotium Gum has uneven particle size distribution of oil droplet.
  • Example 2 oil-in-water emulsions and the stability test
  • oil-in-water emulsions are prepared through formulas in Table 2 (in parts by weight) .
  • Example 3 oil-in-water emulsions and the stability test
  • oil-in-water emulsions are prepared through formulas in Table 3 (in parts by weight) .
  • Example 4 an oil-in-water emulsions and the stability test
  • oil-in-water emulsions are prepared through formulas in Table 4 (in parts by weight) .
  • Example 5 oil-in-water emulsions and the stability test
  • oil-in-water emulsions are prepared through formulas in Table 5 (in parts by weight) .
  • Example 6 a preparation method and application method of a kit for infantile eczema
  • Formula of the first moisturizing cream 30 parts by weight of water, 50 parts by weight of sorbitol, 20 parts by weight of betaine, 0.18 part by weight of Sclerotium Gum, 15 parts by weight of petrolatum and 0.5 part by weight of lactic acid extract.
  • the second aqueous solution 100 parts by weight of purified water.
  • Control experiment the first moisturizing cream was directly applied onto the inner side of the arm to evaluate the skin feeling.
  • the skin feeling comfort is taken as a standard, dryness and moisturizing represents comfortable, sticky and airtight represent uncomfortable.
  • Comfortable 5 scores, relatively comfortable: 4 scores, average: 3 scores, uncomfortable: 2 scores, extreme uncomfortable: 1 score.
  • the moisturizing cream is applied to the affected part of infantile eczema to evaluate the effect of removing infantile eczema.
  • the moisturizing cream of the present disclosure has a good inhibitory effect on infantile eczema.
  • This experiment refers to the microbiological antiseptic efficacy test method of USP39 ⁇ 51 > in the United States Pharmacopoeia, that is, 30 g of each test sample was weighed into a sterilized sample bottle, a quantitative mixed bacterial suspension was added, and the initial bacterial concentration in the sample was 10 6 cfu/g; the initial concentrations of yeast and mold are 10 5 cfu/g.
  • the above substances were uniformly mixed, the mouth of the sample bottle was sealed with sealing glue and then the sample bottle was placed in an incubator at about 28°C. Samples were taken and analyzed at 7, 14, 21 and 28 days after inoculation.
  • the result of the microbial challenge tests of samples of the two emulsion anticorrosive systems in examples 1-1#and 1-2# show that the emulsion can pass the challenge test in personal care products. Accordingly, the personal care emulsion of the present disclosure can take a good anti-corrosive effect on the formula.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
PCT/CN2022/086724 2021-04-27 2022-04-13 Oil-in-water emulsions and uses thereof in resisting infantile eczema Ceased WO2022228134A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/556,825 US20250281443A1 (en) 2021-04-27 2022-04-13 Oil-in-water emulsions and uses thereof in resisting infantile eczema
JP2023565903A JP2024515787A (ja) 2021-04-27 2022-04-13 水中油型エマルションおよび乳児湿疹に耐えることにおけるその使用
EP22794605.0A EP4329719A4 (en) 2021-04-27 2022-04-13 Oil-in-water emulsions and uses thereof in resistance to infant dermatitis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110458173.8A CN115245470A (zh) 2021-04-27 2021-04-27 水包油乳液及其在对抗婴儿湿疹中的用途
CN202110458173.8 2021-04-27

Publications (1)

Publication Number Publication Date
WO2022228134A1 true WO2022228134A1 (en) 2022-11-03

Family

ID=83697281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/086724 Ceased WO2022228134A1 (en) 2021-04-27 2022-04-13 Oil-in-water emulsions and uses thereof in resisting infantile eczema

Country Status (5)

Country Link
US (1) US20250281443A1 (enExample)
EP (1) EP4329719A4 (enExample)
JP (1) JP2024515787A (enExample)
CN (1) CN115245470A (enExample)
WO (1) WO2022228134A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024093989A (ja) * 2022-12-27 2024-07-09 富士フイルム株式会社 化粧料組成物、角層改善剤及び保湿機能改善剤

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045081A2 (en) * 2010-10-01 2012-04-05 Mary Kay Inc. Skin moisturizer and age fighting formula
DE102011077039A1 (de) * 2011-06-07 2012-12-13 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit Polyglyceryl-10-Stearat, Polylysin und Sclerotium Gum
CN106420458A (zh) * 2016-10-10 2017-02-22 大连苗谣青颜生物科技有限公司 祛红肿痒滋养修护霜及其制法
US20180071193A1 (en) * 2016-09-14 2018-03-15 Rodan & Fields, Llc Moisturizing compositions and uses thereof
CN110302087A (zh) * 2019-08-16 2019-10-08 广州立白企业集团有限公司 修护组合物、应用及含有该修护组合物的护肤品组合物
KR102176812B1 (ko) * 2020-04-03 2020-11-10 한국콜마주식회사 천연 유화제를 포함하는 수중유형의 화장료 조성물
CN112451402A (zh) * 2020-12-28 2021-03-09 刘溪金 一种修复补水面膜液及其面膜和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227813A (en) * 1988-02-10 1990-03-27 Richardson Vicks Inc Oil in water emulsion having 3-40% oil and an amphipathic emulsifying agent in the range 0.02-2% and method of forming such emulsions
WO2001070271A2 (en) * 2000-03-23 2001-09-27 Collaborative Technologies, Inc. Acid-stable base compositions for preparing surfactant free topical compositions
FR2822068B1 (fr) * 2001-03-15 2004-12-17 Pharmascience Lab Composition topique comprenant une association de lipides furanniques d'avocat et d'isoflavones
WO2003041667A2 (en) * 2001-11-13 2003-05-22 The Procter & Gamble Company Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
FR2841470B1 (fr) * 2002-06-27 2006-01-13 Pharmascience Lab Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee
FR2856294B1 (fr) * 2003-06-18 2005-08-05 Expanscience Lab Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite
JP2005263781A (ja) * 2004-02-18 2005-09-29 Kose Corp アルカリ性化粧料
JP2007106694A (ja) * 2005-10-13 2007-04-26 Shiseido Co Ltd 皮膚外用剤
JP4722683B2 (ja) * 2005-12-02 2011-07-13 株式会社マンダム 皮膚用乳化組成物
WO2007066642A1 (ja) * 2005-12-05 2007-06-14 Kyowa Hakko Kogyo Co., Ltd. 皮膚の乾燥予防または改善用経口剤
JP4817435B2 (ja) * 2006-04-26 2011-11-16 株式会社コスモステクニカルセンター 皮膚外用剤
US20140315991A1 (en) * 2008-10-21 2014-10-23 Novodermix International Limited Composition for treatment of epithelial tissue
CN102256602A (zh) * 2008-10-21 2011-11-23 诺沃德米克斯国际有限公司 用于治疗上皮组织的组合物
JP5851726B2 (ja) * 2011-05-24 2016-02-03 花王株式会社 水中油型乳化メイクアップ化粧料
JP6473607B2 (ja) * 2014-11-26 2019-02-20 株式会社ダリヤ 乳化組成物
US10722461B2 (en) * 2015-06-19 2020-07-28 Global Health Solutions, Llc Petrolatum-based delivery systems and for active ingredients
CN104958358A (zh) * 2015-07-24 2015-10-07 王玉生 治疗银屑病的中药组合物及其制备方法
CN105963432A (zh) * 2016-03-30 2016-09-28 安徽金马药业有限公司 一种消炎镇痛膏
CN109288687A (zh) * 2018-12-11 2019-02-01 华东理工大学 一种多功效液晶面膜液及其制备方法
CN113677688A (zh) * 2019-03-26 2021-11-19 山东本真化妆品有限公司 个人护理组合物及其用途
US20200306263A1 (en) * 2019-03-27 2020-10-01 The Theraplex Company, LLC Topical formulation for inflammatory skin conditions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012045081A2 (en) * 2010-10-01 2012-04-05 Mary Kay Inc. Skin moisturizer and age fighting formula
DE102011077039A1 (de) * 2011-06-07 2012-12-13 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen mit Polyglyceryl-10-Stearat, Polylysin und Sclerotium Gum
US20180071193A1 (en) * 2016-09-14 2018-03-15 Rodan & Fields, Llc Moisturizing compositions and uses thereof
CN106420458A (zh) * 2016-10-10 2017-02-22 大连苗谣青颜生物科技有限公司 祛红肿痒滋养修护霜及其制法
CN110302087A (zh) * 2019-08-16 2019-10-08 广州立白企业集团有限公司 修护组合物、应用及含有该修护组合物的护肤品组合物
KR102176812B1 (ko) * 2020-04-03 2020-11-10 한국콜마주식회사 천연 유화제를 포함하는 수중유형의 화장료 조성물
CN112451402A (zh) * 2020-12-28 2021-03-09 刘溪金 一种修复补水面膜液及其面膜和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
31 December 1998, ISBN: 7-5639-0663-0, article LIU， CHENG ET AL.: "Sclerotium Gum emulsified oil products，", pages: 843 - 848, XP009540597 *
See also references of EP4329719A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024093989A (ja) * 2022-12-27 2024-07-09 富士フイルム株式会社 化粧料組成物、角層改善剤及び保湿機能改善剤

Also Published As

Publication number Publication date
EP4329719A1 (en) 2024-03-06
CN115245470A (zh) 2022-10-28
US20250281443A1 (en) 2025-09-11
EP4329719A4 (en) 2025-03-26
JP2024515787A (ja) 2024-04-10

Similar Documents

Publication Publication Date Title
CN104812398B (zh) 局部组合物及其使用方法
BR102016017090B1 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
TW201924701A (zh) 皮膚微生物調飾之方法與局部組成物
WO2017087640A1 (en) Probiotic treatment of skin diseases, disorders, and infections: formulations, methods and systems
CN106344465A (zh) 一种不含防腐剂的保湿乳液
JP2016531948A (ja) 組成物
TW202112351A (zh) 局部組成物及其相關方法
CN105816848A (zh) 一种祛湿防护膏及其制备方法
JP2002068957A (ja) 乳化型皮膚外用剤
CN112022895A (zh) 一种用于皮肤屏障修复的组合物及其制备方法
US20250281443A1 (en) Oil-in-water emulsions and uses thereof in resisting infantile eczema
JP2001233754A (ja) 乳化型皮膚外用剤
US20100048740A1 (en) Naturally Derived Emulsifier System
EP0375082A2 (en) Cosmetic composition
AU2009256524A1 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
WO2021085293A1 (ja) セルライト改善用皮膚外用剤、およびセルライト改善方法
CN101203277B (zh) 毛发滋补剂
EP2192956B1 (de) Kosmetische oder dermatologische zusammensetzung zur topischen verwendung
JP6826883B2 (ja) Ｍａｌａｓｓｅｚｉａ属真菌に対する増殖抑制剤、Ｍａｌａｓｓｅｚｉａ属真菌性皮膚疾患の予防乃至治療剤、及びＭａｌａｓｓｅｚｉａ属真菌の除菌、除去乃至増殖抑制方法
JP5642924B2 (ja) 皮膚バリア機能回復促進用水中油型乳化組成物
EP3175839A1 (en) Skin care composition
JP4703809B2 (ja) 皮膚外用剤
JP3556479B2 (ja) 皮膚プレトリートメント剤
JP4295841B2 (ja) 抗アレルギー外用剤
KR20220082832A (ko) 피부 미생물총의 다양성을 증가시키기 위한 n-메틸글리신의 신규한 화장품 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22794605

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023565903

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022794605

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022794605

Country of ref document: EP

Effective date: 20231127

WWP Wipo information: published in national office

Ref document number: 18556825

Country of ref document: US